COVID-19 Bivalent Booster in Pregnancy: Maternal and Neonatal Antibody Response to Omicron BA.5, BQ.1, BF.7 and XBB.1.5 SARS-CoV-2

COVID-19 Bivalent Booster in Pregnancy: Maternal and Neonatal Antibody Response to Omicron BA.5, BQ.1, BF.7 and XBB.1.5 SARS-CoV-2

Our study was to investigate the effects of bivalent COVID-19 booster vaccination during pregnancy on neutralizing antibody (Nab) levels in maternal blood (MB), transplacental transmission in umbilical cord blood (CB), and efficacy against Omicron SARS-CoV-2 subvariants including BA.5, BF.7, BQ.1, a...

Full description

Bibliographic Details
Main Authors:	Wei-Chun Chen, Shu-Yu Hu, Ching-Fen Shen, Hui-Yu Chuang, Chin-Ru Ker, Ching-Ju Shen, Chao-Min Cheng
Format:	Article
Language:	English
Published:	MDPI AG 2023-08-01
Series:	Vaccines
Subjects:	bivalent COVID-19 booster vaccines SARS-CoV-2 Omicron subvariants BA.5 BF.7 BQ.1
Online Access:	https://www.mdpi.com/2076-393X/11/9/1425

Similar Items

Vaccine Confidence and Uptake of the Omicron Bivalent Booster in Tennessee: Implications for Vulnerable Populations
by: Donald J. Alcendor, et al.
Published: (2023-04-01)

Neutralizing antibody response to XBB.1.5, BA.2.86, FL.1.5.1, and JN.1 six months after the BNT162b2 bivalent booster
by: Julien Favresse, et al.
Published: (2024-06-01)

Can the RBD mutation R346X provide an additional fitness to the “variant soup,” including offspring of BQ and XBB of SARS-CoV-2 Omicron for the antibody resistance?
by: Srijan Chatterjee, et al.
Published: (2023-06-01)

Effectiveness and durability of mRNA-1273 BA.4/BA.5 bivalent vaccine (mRNA-1273.222) against SARS-CoV-2 BA.4/BA.5 and XBB sublineages
by: Bradley K. Ackerson, et al.
Published: (2024-12-01)

The rapid rise of SARS‐CoV‐2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants
by: Danyi Ao, et al.
Published: (2023-04-01)

Effect of second booster vaccination on clinical outcomes of Omicron-variant breakthrough infection: A propensity score matching cohort study
by: Denggao Peng, et al.
Published: (2024-01-01)

Emergence and geographic dominance of Omicron subvariants XBB/XBB.1.5 and BF.7 – the public health challenges
by: Thirumalaisamy P. Velavan, et al.
Published: (2023-03-01)

Cross-neutralizing antibody against emerging Omicron subvariants of SARS-CoV-2 in infection-naïve individuals with homologous BNT162b2 or BNT162b2(WT + BA.4/5) bivalent booster vaccination
by: Samuel M.S. Cheng, et al.
Published: (2024-03-01)

Assessment of neutralization susceptibility of Omicron subvariants XBB.1.5 and BQ.1.1 against broad-spectrum neutralizing antibodies through epitopes mapping
by: Masaud Shah, et al.
Published: (2023-09-01)

Twitter-Based Sentiment Analysis and Topic Modeling of Social Media Posts using Natural Language Processing, to Understand People’s Perspectives Regarding COVID-19 Omicron Subvariants XBB.1.5 and BF.7
by: S.V. Praveen, et al.
Published: (2023-03-01)

Modelling the potential public health impact of different vaccination strategies with an omicron-adapted bivalent vaccine in Thailand
by: Karan Thakkar, et al.
Published: (2023-12-01)

Modeling the potential public health impact of different vaccination strategies with an omicron-adapted bivalent vaccine in Malaysia
by: Karan Thakkar, et al.
Published: (2023-12-01)

Neutralizing Activity against BQ.1.1, BN.1, and XBB.1 in Bivalent COVID-19 Vaccine Recipients: Comparison by the Types of Prior Infection and Vaccine Formulations
by: Hak-Jun Hyun, et al.
Published: (2023-08-01)

Effectiveness of the severe acute respiratory syndrome coronavirus 2 Omicron BA.5 bivalent vaccine on symptoms in healthcare workers with BA.5 infection
by: Yosuke Hirotsu, et al.
Published: (2024-03-01)

Relative effectiveness of bivalent COVID-19 vaccine: a systematic review and meta-analysis
by: Meng-qun Cheng, et al.
Published: (2024-02-01)

The emergence of the Omicron XBB.1.5 variant in India: a brief report on clinical presentation of a few cases
by: Jasmine Samal, et al.
Published: (2023-06-01)

Mapping the Early Dispersal Patterns of SARS-CoV-2 Omicron BA.4 and BA.5 Subvariants in the Absence of Travel Restrictions and Testing at the Borders in Europe
by: Evangelia Georgia Kostaki, et al.
Published: (2022-12-01)

Omicron subvariant BA.5 is highly contagious but containable: Successful experience from Macau
by: Cong Xu, et al.
Published: (2023-01-01)

Bivalent second booster dose of the COVID-19 vaccine: Eligible populations’ reasons for receiving in Italy
by: Giorgia Della Polla, et al.
Published: (2023-01-01)

Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS‐CoV‐2 Omicron BA.1 variant
by: Zhongcheng Zhou, et al.
Published: (2022-06-01)

Could the New BA.2.75 Sub-Variant Cause the Emergence of a Global Epidemic of COVID-19? A Scoping Review
by: Shaheen N, et al.
Published: (2022-10-01)

Characteristics of the First 284 Patients Infected with the SARS-CoV-2 Omicron BA.2 Subvariant at a Single Center in the Apulia Region of Italy, January–March 2022
by: Daniela Loconsole, et al.
Published: (2022-04-01)

Vitamin D levels and clinical outcomes of SARS-CoV-2 Omicron subvariant BA.2 in children: A longitudinal cohort study
by: Denggao Peng, et al.
Published: (2022-07-01)

XBB.1.16 Omicron subvariant rise to a variant of interest: Implications for global alertness and preparedness
by: Okesanya Olalekan John, B'MLS, et al.
Published: (2023-12-01)

The evolution of vaccine hesitancy through the COVID-19 pandemic: A semi-structured interview study on booster and bivalent doses
by: Jeanna Parsons Leigh, et al.
Published: (2024-12-01)

Differences in clinical characteristics and liver injury between patients diagnosed with the Omicron subvariant BA.5.2 and the prototype of SARS-CoV-2: a single center retrospective study
by: Jie Li, et al.
Published: (2023-08-01)

Monovalent Omicron COVID-19 vaccine triggers superior neutralizing antibody responses against Omicron subvariants than Delta and Omicron bivalent vaccine
by: Wanting Li, et al.
Published: (2023-08-01)

SARS-CoV-2 Neutralization Capacity in Hemodialysis Patients with and without a Fifth Vaccination with the Updated Comirnaty Original/Omicron BA.4-5 Vaccine
by: Bo-Hung Liao, et al.
Published: (2024-03-01)

Redistribution and Activation of CD16brightCD56dim NK Cell Subset to Fight against Omicron Subvariant BA.2 after COVID-19 Vaccination
by: Huiyun Peng, et al.
Published: (2023-04-01)

Transmission characteristics and inactivated vaccine effectiveness against transmission of the SARS-CoV-2 Omicron BA.2 variant in Shenzhen, China
by: Xiaofeng He, et al.
Published: (2024-01-01)

Modelling the impact of a high-uptake bivalent booster scenario on the COVID-19 burden and healthcare costs in New York CityResearch in context
by: Abhishek Pandey, et al.
Published: (2023-08-01)

A Heterologous V-01 or Variant-Matched Bivalent V-01D-351 Booster following Primary Series of Inactivated Vaccine Enhances the Neutralizing Capacity against SARS-CoV-2 Delta and Omicron Strains
by: Zhiren Zhang, et al.
Published: (2022-07-01)

Effectiveness of Bivalent Omicron-Containing Booster Vaccines against SARS-CoV-2 Omicron Variant among Individuals with and without Prior SARS-CoV-2 Infection
by: Kristin Widyasari, et al.
Published: (2023-08-01)

Second booster dose improves antibody neutralization against BA.1, BA.5 and BQ.1.1 in individuals previously immunized with CoronaVac plus BNT162B2 booster protocol
by: Guilherme R. F. Campos, et al.
Published: (2024-04-01)

Role of booster vaccines and hybrid immunity against severe COVID-19 outcomes during BA.5 omicron predominance in Thailand
by: Kannikar Intawong, et al.
Published: (2023-12-01)

The importance of booster vaccination in the context of Omicron wave
by: Zichun Wei, et al.
Published: (2022-09-01)

Equitable bivalent booster allocation strategies against emerging SARS-CoV-2 variants in US cities with large Hispanic communities: The case of El Paso County, Texas
by: Francis Owusu-Dampare, et al.
Published: (2023-09-01)

Monovalent XBB.1.5 booster vaccination induces a broad spectrum of SARS-CoV-2 neutralizing antibodies
by: Nan Huo, et al.
Published: (2024-12-01)

The Omicron variant of concern: The genomics, diagnostics, and clinical characteristics in children
by: Djatnika Setiabudi, et al.
Published: (2022-08-01)

The fourth COVID-19 vaccine dose increased the neutralizing antibody response against the SARS-CoV-2 Omicron (B.1.1.529) variant in a diverse Brazilian population
by: Jéssica Pires Farias, et al.
Published: (2023-12-01)